Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
about
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid CancerModulation of sodium iodide symporter in thyroid cancermiRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.Novel targeted therapies and immunotherapy for advanced thyroid cancers.Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway
P2860
Q26744936-653675E0-D7A2-47A4-8791-907184AA4777Q35690173-8A3388FE-AE0F-4D49-88F0-802F1C4BD344Q37035505-90195100-DF3C-4A47-B47F-112E235BE49BQ37580248-AF5FE104-6268-459D-B563-304F998D9E36Q38673964-702BED09-52BD-479E-982B-F4D59F539740Q38675367-199787B6-6B38-4BBD-AA28-E102DF0C3FBCQ38754489-5CC66EE7-F561-40B3-878D-D816FDF91C5EQ38972528-C6AA397C-9B12-40CD-B753-5CE474A337D0Q40853145-946EBE27-7DCC-49ED-9013-CF6A7E116935Q48098904-0C112B49-08CD-483E-9562-33F0D877E3D4Q49887965-CA14A8E6-CD0D-4C52-AA15-4EA8024981E6Q52691334-77486057-DBB1-412D-BC5F-E68B170BED36Q54217447-1FCDE2E5-58B5-4493-A01F-4BB35465709CQ57494116-0679050F-E9F1-4919-B9FF-39D05A784607
P2860
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Advanced radioiodine-refractor ...... emerging therapeutic targets.
@en
type
label
Advanced radioiodine-refractor ...... emerging therapeutic targets.
@en
prefLabel
Advanced radioiodine-refractor ...... emerging therapeutic targets.
@en
P2093
P1476
Advanced radioiodine-refractor ...... emerging therapeutic targets.
@en
P2093
Christine Spitzweg
John C Morris
Keith C Bible
P304
P356
10.1016/S2213-8587(14)70051-8
P577
2014-06-02T00:00:00Z